BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gatti M, Cojutti PG, Pascale R, Tonetti T, Laici C, Dell'Olio A, Siniscalchi A, Giannella M, Viale P, Pea F. Assessment of a PK/PD Target of Continuous Infusion Beta-Lactams Useful for Preventing Microbiological Failure and/or Resistance Development in Critically Ill Patients Affected by Documented Gram-Negative Infections. Antibiotics (Basel) 2021;10:1311. [PMID: 34827249 DOI: 10.3390/antibiotics10111311] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Gatti M, Tedeschi S, Trapani F, Ramirez S, Mancini R, Giannella M, Viale P, Pea F. A Proof of Concept of the Usefulness of a TDM-Guided Strategy for Optimizing Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Ampicillin-Based Regimens in a Case Series of Patients with Enterococcal Bloodstream Infections and/or Endocarditis. Antibiotics 2022;11:1037. [DOI: 10.3390/antibiotics11081037] [Reference Citation Analysis]
2 Sanz Codina M, Gatti M, Troisi C, Fornaro G, Pasquini Z, Trapani F, Zanoni A, Caramelli F, Viale P, Pea F. Relationship between Pharmacokinetic/Pharmacodynamic Target Attainment and Microbiological Outcome in Critically Ill COVID-19 Patients with Documented Gram-Negative Superinfections Treated with TDM-Guided Continuous-Infusion Meropenem. Pharmaceutics 2022;14:1585. [DOI: 10.3390/pharmaceutics14081585] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Gatti M, Cojutti PG, Bartoletti M, Tonetti T, Bianchini A, Ramirez S, Pizzilli G, Ambretti S, Giannella M, Mancini R, Siniscalchi A, Viale P, Pea F. Expert clinical pharmacological advice may make an antimicrobial TDM program for emerging candidates more clinically useful in tailoring therapy of critically ill patients. Crit Care 2022;26:178. [PMID: 35701812 DOI: 10.1186/s13054-022-04050-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Losito AR, Raffaelli F, Del Giacomo P, Tumbarello M. New Drugs for the Treatment of Pseudomonas aeruginosa Infections with Limited Treatment Options: A Narrative Review. Antibiotics 2022;11:579. [DOI: 10.3390/antibiotics11050579] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
5 Hamada Y, Kasai H, Suzuki-ito M, Matsumura Y, Doi Y, Hayakawa K. Pharmacokinetic/Pharmacodynamic Analysis and Dose Optimization of Cefmetazole and Flomoxef against Extended-Spectrum β-Lactamase-Producing Enterobacterales in Patients with Invasive Urinary Tract Infection Considering Renal Function. Antibiotics 2022;11:456. [DOI: 10.3390/antibiotics11040456] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Gatti M, Viaggi B, Rossolini GM, Pea F, Viale P. An Evidence-Based Multidisciplinary Approach Focused on Creating Algorithms for Targeted Therapy of Infection-Related Ventilator-Associated Complications (IVACs) Caused by Pseudomonas aeruginosa and Acinetobacter baumannii in Critically Ill Adult Patients. Antibiotics (Basel) 2021;11:33. [PMID: 35052910 DOI: 10.3390/antibiotics11010033] [Cited by in F6Publishing: 3] [Reference Citation Analysis]